← All trials
NCT03673462
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2018
- Primary completion
- Apr 30, 2021
- Completion date
- Apr 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 3080
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- measles, mumps, and rubella vaccine
- inactivated varicella vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- tetanus toxoid
- human rotavirus, live attenuated
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.